Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Non-Executive Non-Independent Director Upendar Reddy was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹177, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 65% over the past three years. Announcement • Jun 22
Bafna Pharmaceuticals Limited Announces Board and Committee Changes Bafna Pharmaceuticals Limited informed that Mr. Navin Kumar (DIN: 08778662) will be retiring as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026. Consequently, he also ceased to be the Chairman of the Audit Committee and the Nomination & Remuneration Committee of the Company. The following Committees of the Board of Directors have been re-constituted with effect from June 23, 2026: Audit Committee: Mr. Palamadai Krishnan Sundaresan, Chairman (Non-Executive, Independent); Mrs. Ravichandran Chitra, Member (Non-Executive, Independent); Mr. Upendar Mekala Reddy, Member (Non-Executive, Non-Independent). Nomination and Remuneration Committee: Mr. Palamadai Krishnan Sundaresan, Chairman (Non-Executive, Independent); Mrs. Ravichandran Chitra, Member (Non-Executive, Independent); Mrs. Akila Chintalapati Raju, Member (Non-Executive, Non-Independent). The composition of the Board and its Committees continues to remain in compliance with the requirements of the applicable laws.